论文部分内容阅读
药物控制支气管哮喘的疗效、耐药性等取决于选用或伍用药物对特定患者是否适宜。作者就近年若干新药选择及用法予以评价。β肾上腺素能气雾剂:适用于偶发患者,但过量或滥用易致心血管及呼吸系副作用。新型气雾剂长效间羟肾上腺素(Metaproterenol sulfale)不降低氧甲基转移酶活性,较少心脏毒性。异丙肾上腺素及苯肾上腺素(新福林)等主要选择性作用于β_2受体(支气管扩张),对β_1受体(心脏)作用微弱。最近可供选择的新药还有舒喘灵
The efficacy of drug control bronchial asthma, drug resistance, etc., depends on the choice or drug is suitable for a particular patient. The author evaluates several new drug options and usage in recent years. Beta-adrenergic aerosol: For occasional patients, but excessive or abuse prone to cause cardiovascular and respiratory effects. The new aerosol long-acting metanephrine (Metaproterenol sulfale) does not reduce the oxygen methyltransferase activity, less cardiotoxicity. Isoprenaline and phenylephrine (Neo-Fulin) and other major selective role in β 2 receptor (bronchiectasis), β 1 receptor (heart) weak. Recent options for new drugs are salbutamol